Alterity Therapeutics to Host Virtual KOL Event on New Insights for MSA Treatment

Event to feature experts discussing unmet need, current landscape, and planned Phase 3 trial for ATH434

Apr. 15, 2026 at 11:34am

Got story updates? Submit your updates here. ›

An extreme close-up X-ray image revealing the intricate internal structures of the human brain, conceptually representing the complex neurological processes involved in Multiple System Atrophy.A detailed X-ray view of the human brain highlights the complex neurological challenges in treating Multiple System Atrophy, a rare and rapidly progressive neurodegenerative disorder.Boston Today

Alterity Therapeutics, a biotechnology company focused on neurodegenerative diseases, announced it will host a virtual key opinion leader (KOL) event to discuss its lead candidate ATH434 and the current state of Multiple System Atrophy (MSA) treatment. The event will feature presentations from Harvard's Roy Freeman, MD, and Vanderbilt's Daniel Claassen, MD, alongside Alterity's CEO David Stamler, MD.

Why it matters

MSA is a rare, rapidly progressive neurodegenerative disorder with no approved treatments. Alterity's ATH434 has shown promising results in Phase 2 trials and the company is preparing to initiate a Phase 3 pivotal study, making this virtual event an important opportunity to share new insights on the drug's potential and the unmet need in this devastating disease.

The details

The virtual KOL event will provide an overview of ATH434, Alterity's lead candidate that is a potential first-in-class, disease-modifying therapy for MSA. The experts will also review the MSA disease background and current treatment landscape, discuss new analyses from the Phase 2 program, and give a high-level overview of Alterity's planned Phase 3 trial.

  • The virtual KOL event will take place on April 15, 2026.

The players

Roy Freeman, MD

Professor of Neurology at Harvard Medical School and director of the Center for Autonomic and Peripheral Nerve Disorders at Beth Israel Deaconess Medical Center.

Daniel Claassen, MD, MS

Professor of Neurology at Vanderbilt University Medical Center, expert in neurodegenerative diseases, and Chief Medical Advisor to Alterity Therapeutics.

David Stamler, MD

CEO of Alterity Therapeutics.

Alterity Therapeutics

A biotechnology company dedicated to developing disease-modifying treatments for neurodegenerative diseases, including Multiple System Atrophy.

Got photos? Submit your photos here. ›

What they’re saying

“We must not let individuals continue to damage private property in San Francisco.”

— Robert Jenkins, San Francisco resident

What’s next

The virtual KOL event will provide a high-level overview of Alterity's planned Phase 3 program for ATH434 in MSA.

The takeaway

This event highlights the significant unmet need in treating MSA, a rare and devastating neurodegenerative disorder, and Alterity's efforts to advance a potential first-in-class therapy through late-stage clinical development.